insulin glargine The SURPASS-AP-Combo trial enrolled 917 adults with type 2 diabetes (age 18 years, inadequately controlled by previous metformin therapy and insulin-naive), who received tirzepatide 5 mg (n = 230), 10 mg (n = 228), 15 mg (n = 229), or insulin glargine (n = 230)
Its also possible that one medication could be more effective or cause fewer side effects compared to another, even though the medicines work in a similar way
Read the full review
Although it is not a typical side effect, some users have experienced hair loss while taking Wegovy 1mg
Product pages provide important specifications such as peptide name, concentration, package size, and dosage form whenever available
Notwithstanding the novelty of the current study, it is essential to acknowledge several limitations